New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 23, 2014
06:54 EDTLH, MYGNMyriad remains in Horizon New Jersey network, says William Blair
William Blair believes there is confusion around Horizon BCBS of New Jersey's BRCA commentary, which it feels attributed to the recent pullback in shares of Myriad Genetics (MYGN). The firm said Horizon reiterated LabCorp's (LH) preferred network status and suggested that doctors should use LabCorp for BRCA testing. The insurer does not refer to a change in Myriadís network status as a participating provider in Horizonís network, the firm points out. William Blair says it has not seen evidence that Myriad is being excluded as a network provider. It maintains an Outperform rating on the stock.
News For MYGN;LH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
07:17 EDTMYGNSociety of Thoracic Surgeons to hold annual meeting
51st Annual Meeting of STS is being held in San Diego, California on January 24-28.
January 25, 2015
20:22 EDTLHA small miss for LabCorp could cause a share drop, Barron's says
Subscribe for More Information
January 23, 2015
15:46 EDTMYGNPiper Jaffray's medtech analysts hold an analyst/industry conference call
Subscribe for More Information
07:32 EDTLHCharles River Labs upgraded to Outperform from Market Perform at William Blair
William Blair upgraded Charles River Labs (CRL) to Outperform citing improving demand for early-stage development services as well as opportunity for share gains due to Covanceís (CVD) pending merger with LabCorp (LH).
January 20, 2015
08:21 EDTLHLabCorp upgraded to Buy from Hold at Evercore ISI
Subscribe for More Information
07:07 EDTMYGNMyriad RBM joins Institut Pasteur in TB collaboration
Myriad RBM, a wholly owned subsidiary of Myriad Genetics, announced that it will assist the Institut Pasteur in a public-private research collaboration to fight the global tuberculosis, or TB, epidemic. This research project is funded by the Bill & Melinda Gates Foundation through a grant to the Institut Pasteur. The proof-of-concept study will evaluate patients with latent and active TB infections who are affiliated with the South African Tuberculosis Vaccine Initiative clinical study sites. The goals of this study are to field-test Myriad RBM's TruCulture system as a point-of-care blood collection and immune response monitoring method and to stratify patients with active and latent tuberculosis.
January 15, 2015
07:59 EDTMYGNAmerican Society of Clinical Oncology to hold a symposium
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use